4D Molecular Therapeutics Inc
(FDMT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -49,306 | N/A | N/A | N/A |
| Depreciation Amortization | 1,004 | N/A | N/A | N/A |
| Accounts receivable | 146 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 533 | N/A | N/A | N/A |
| Other Working Capital | 259 | N/A | N/A | N/A |
| Other Operating Activity | 10,653 | 0 | 0 | 0 |
| Operating Cash Flow | $-36,711 | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -3,203 | N/A | N/A | N/A |
| Investing Cash Flow | $-3,203 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | -2,185 | N/A | N/A | N/A |
| Other Financing Activity | -10 | 0 | 0 | 0 |
| Financing Cash Flow | $-2,195 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 91,761 | N/A | N/A | N/A |
| End Cash Position | 49,652 | N/A | N/A | N/A |
| Net Cash Flow | $-42,109 | $N/A | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -36,711 | N/A | N/A | N/A |
| Capital Expenditure | -3,203 | N/A | N/A | N/A |
| Free Cash Flow | -39,914 | 0 | 0 | 0 |